The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A00003847" target="_blank" >RIV/00216208:11120/12:00003847 - isvavai.cz</a>
Alternative codes found
RIV/00064211:_____/12:#0000124
Result on the web
<a href="http://dx.doi.org/10.1007/s00280-011-1772-z" target="_blank" >http://dx.doi.org/10.1007/s00280-011-1772-z</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00280-011-1772-z" target="_blank" >10.1007/s00280-011-1772-z</a>
Alternative languages
Result language
angličtina
Original language name
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer
Original language description
Bexarotene (Targretin capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metabolism. This phase I trial evaluated the pharmacokinetic (PK) and drug-drug interactions of bexarotene with chemotherapy and a lipid-lowering agent (atorvastatin or fenofibrate). This trial was run in parallel with phase III trials of the combinations to determine whether repeated doses of bexarotene capsules affect the pharmacokinetics (PK) of the chemotherapeutic or the lipid-lowering agents. Here, we report the drug-drug interactions between the lipid-lowering agents and bexarotene. Mean atorvastatin clearance and dose-corrected AUC values were reduced by nearly 50% with the addition of concomitant bexarotene. As fenofibrate was less effective at controlling hypertriglyceridemia, too few patients received this agent to make any meaningful conclusions about drug-drug interactions. A drug-drug interaction was seen in this trial with bexarotene co-administration leading to a significa
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer Chemotherapy and Pharmacology
ISSN
0344-5704
e-ISSN
—
Volume of the periodical
69
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
563-571
UT code for WoS article
000299516700030
EID of the result in the Scopus database
—